title: Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population.
abstract: Prostate-specific antigen (PSA) is still the cornerstone of prostate cancer (PCa) screening and diagnosis in both research and current clinical practice. Inaccuracy of PSA is partly due to the influence of a number of genetic, clinical, and biological factors modifying PSA blood levels. In the present study, we detailed the respective influence of each factor among age, body mass index (BMI), prostate volume, and five single-nucleotide polymorphisms-rs10788160 (10q26), rs10993994 (10q11), rs11067228 (12q24), rs17632542 (19q13.33), and rs2928679 (8p21)-on PSA values in a cohort of 1374 men without PCa. Our results show that genetic factors, when risk variants are combined, influence PSA levels with an effect size similar to that of BMI. Taken together, the respective correlations of clinical parameters and genetic parameters would make it possible to correct and adjust PSA values more effectively in each individual. These results establish the basis to understand and implement a more personalised approach for the interpretation of PSA blood levels in the context of PCa screening and diagnosis.
  
  
  
  Prostate-specific antigen (PSA) values in an individual may vary according to genetic predisposition. The effect size of this variation can be significant, comparable with those resulting from clinical characteristics. Personalised PSA testing should take this into account.
authors: Academic Department of Urology, Hôpital Tenon, AP-HP, UPMC Université Paris 06, Paris, France.
authors: Jean-Nicolas
authors: JN
authors: Cornu
authors: Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France; GRC no. 5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC Université Paris 06, Paris, France.
authors: Geraldine
authors: G
authors: Cancel-Tassin
authors: INSERM U1052, Cancer Research Center of Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; Centre Léon Bérard, Lyon, France.
authors: David G
authors: DG
authors: Cox
authors: Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France; GRC no. 5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC Université Paris 06, Paris, France; Academic Department of Urology, Hôpital Pitié-Salpétrière, AP-HP, UPMC Université Paris 06, Paris, France.
authors: Morgan
authors: M
authors: Roupret
authors: Academic Department of Urology, CHU Dijon, Dijon, France.
authors: Nicolas
authors: N
authors: Koutlidis
authors: Academic Department of Urology, CHU Angers, Angers, France.
authors: Pierre
authors: P
authors: Bigot
authors: Academic Department of Urology, CHU Brest, Brest, France.
authors: Antoine
authors: A
authors: Valeri
authors: Academic Department of Urology, Hôpital Tenon, AP-HP, UPMC Université Paris 06, Paris, France; Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France; GRC no. 5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC Université Paris 06, Paris, France.
authors: Valerie
authors: V
authors: Ondet
authors: Academic Department of Urology, Hôpital Tenon, AP-HP, UPMC Université Paris 06, Paris, France; Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France; GRC no. 5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC Université Paris 06, Paris, France.
authors: Cécile
authors: C
authors: Gaffory
authors: Academic Department of Urology, CHU Brest, Brest, France.
authors: Georges
authors: G
authors: Fournier
authors: Academic Department of Urology, CHU Angers, Angers, France.
authors: Abdel-Rahmene
authors: AR
authors: Azzouzi
authors: Academic Department of Urology, CHU Dijon, Dijon, France.
authors: Luc
authors: L
authors: Cormier
authors: Academic Department of Urology, Hôpital Tenon, AP-HP, UPMC Université Paris 06, Paris, France; Centre de Recherche sur les Pathologies Prostatiques et Urologiques (CeRePP), Paris, France; GRC no. 5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC Université Paris 06, Paris, France. Electronic address: olivier.cussenot@tnn.aphp.fr.
authors: Olivier
authors: O
authors: Cussenot
mesh_terms: D000367:Age Factors; D015992:Body Mass Index; D027682:Cation Transport Proteins / Q000235:genetics; D005838:Genotype; D006801:Humans; D007610:Kallikreins / Q000235:genetics; D008297:Male; D024101:Mitochondrial Proteins / Q000235:genetics; D009929:Organ Size; D020641:Polymorphism, Single Nucleotide; D011467:Prostate / Q000033:anatomy & histology*; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000235:genetics; D029584:Prostatic Secretory Proteins / Q000235:genetics; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics; D020825:T-Box Domain Proteins / Q000235:genetics
chemical_list: D027682:Cation Transport Proteins; D024101:Mitochondrial Proteins; D029584:Prostatic Secretory Proteins; C561492:Slc25a37 protein, human; D020825:T-Box Domain Proteins; C106884:TBX3 protein, human; C043076:beta-microseminoprotein; C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen
keywords: Prostate cancer; Prostate-specific antigen; Single-nucleotide polymorphisms